Bushu Pharmaceuticals is a leading Japanese CDMO with over 35 years of experience in drug product manufacturing and packaging for oral solid dosage and injectables. Developed from legacy affiliations with Sandoz, Novartis and Shionogi & Co., Bushu serves global markets from three cGMP manufacturing and development facilities in Japan. In 2017, Bushu Group, the parent company of Bushu Pharmaceuticals, merged with Spera Pharma, which had previously spun out of Takeda Pharmaceutical Company. As the leading CDMO in Japan, Bushu supports clients across the full spectrum of drug development, maintaining exceptionally long records of quality and regulatory compliance across its facilities.